The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
How molecular imaging is speeding up antiangiogenic drug development
Abstract
Drug development is a long process that generally spans about 10 to 15 years. The shift in recent drug discovery to novel agents against specific molecular targets highlights the need for more robust molecular imaging platforms. Using molecular probes, molecular imaging can aid in many steps of the drug development process, such as providing whole body readout in an intact system, decreasing the workload and speeding up drug development/validation, and facilitating individualized anticancer treatment monitoring and dose optimization. The main focus of this review is the recent advances in tumor angiogenesis imaging, and the targets include vascular endothelial growth factor and vascular endothelial growth factor receptor, integrin αvβ3, matrix metalloproteinase, endoglin (CD105), and E-selectin. Through tumor angiogenesis imaging, it is expected that a robust platform for understanding the mechanisms of tumor angiogenesis and evaluating the efficacy of novel antiangiogenic therapies will be developed, which can help antiangiogenic drug development in both the preclinical stage and the clinical settings. Molecular imaging has enormous potential in improving the efficiency of the drug development process, including the specific area of antiangiogenic drugs. [Mol Cancer Ther 2006;5(11):2624–33]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
RGD AND OTHER RECOGNITION SEQUENCES FOR INTEGRINS
Ruoslahti, E. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.697 · Cited by 3,191 · cited 1×
“Imaging Integrin AvB3 Expression Integrins are a family of cell adhesion molecules consisting of two noncovalently bound transmembrane subunits (a and h), both type I membrane proteins with large extracellular segments that pair to create heterodimers with distinct adhesive capabilities (29).”
BackgroundVEGF and the quest for tumour angiogenesis factors
Ferrara, N. (2002) · Nature Reviews Cancer · doi:10.1038/nrc909 · Cited by 1,536
Strategies for MMP inhibition in cancer: innovations for the post-trial era
Overall, C. M., & López-Otín, C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc884 · Cited by 1,349
Cited by
Molecular imaging in drug development
Willmann, J. K., van Bruggen, N., Dinkelborg, L. M., & Gambhir, S. S. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2290 · Cited by 1,171
Self-citationRecent Advances of Optical Imaging in the Second Near‐Infrared Window
Kenry, Duan, Y., & Liu, B. (2018) · Advanced Materials · doi:10.1002/adma.201802394 · Cited by 810
Siemann, D. W. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.001 · Cited by 611
Nanoplatforms for Targeted Molecular Imaging in Living Subjects
Cai, W., & Chen, X. (2007) · Small · doi:10.1002/smll.200700351 · Cited by 563
Self-citationMultimodality Molecular Imaging of Tumor Angiogenesis
Cai, W., & Chen, X. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045922 · Cited by 494
Self-citation
Metadata
- Authors
- Cai, W., Rao, J., Gambhir, S. S., & Chen, X.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2006-11-01
- Volume
- 5
- Issue
- 11
- Pages
- 2624-2633
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2163830997
- Cited by
- 175
- References
- 5
- FWCI
- 6.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How molecular imaging is speeding up antiangiogenic drug development. https://app.cochat.ai/papers/10.1158/1535-7163.mct-06-0395
- The paper
- Cai, W., Rao, J., Gambhir, S. S., & Chen, X. (2006). How molecular imaging is speeding up antiangiogenic drug development. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-06-0395
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.